Quotient Bioscience Group Forms New Biodiagnostics Division

Appoints Jeremy Stackawitz as President and CEO of Quotient Biodiagnostics

April 07, 2009 

CAMBRIDGESHIRE, UK - Quotient Bioscience Group Limited (“Quotient Bioscience”), a leading European provider of analytical and safety evaluation services and products for bioscience and sport, today announces the formation of Quotient Biodiagnostics, a separately managed operation within the Quotient Bioscience Group responsible for the Group’s interests in the diagnostics market. The formation of the new division will allow Quotient Bioscience to build on the success of Alba Bioscience, Quotient Bioscience’s existing diagnostics business which is focused on the manufacture and sale of blood-typing reagents and systems for the OEM (Original Equipment Manufacturers) market. Alba Bioscience was acquired by Quotient Bioscience in August 2007.

The existing OEM business of Quotient Bioscience will continue to trade as Alba Bioscience and focus on the manufacture and supply of bulk reagents and finished goods and will be based in Edinburgh, Scotland. It will become a wholly-owned subsidiary of Quotient Biodiagnostics. The Group’s new commercial operations will trade as Quotient Biodiagnostics.

The principal focus of Quotient Biodiagnostics will be to continue its successful strategy of supplying raw materials and finished goods to the OEM market, develop new products and technologies to serve the worldwide diagnostics market and build a commercial operation (initially in North America) to market and sell the Group’s world leading range of products for blood typing and screening. Quotient Biodiagnostics has an existing range of FDA-licensed products, which is expected to expand significantly over the next twelve to eighteen months.

Commenting on the formation of the new biodiagnostics division, Paul Cowan, Chairman and CEO of Quotient Bioscience said: “The creation of Quotient Biodiagnostics represents the next step in the building of Quotient Bioscience’s diagnostics operations. Alba Bioscience will continue to play a key role in the growth of Quotient Biodiagnostics. The formation of the new division allows us to build on the tremendous success of Alba in recent years.”

Quotient Bioscience also announces the appointment of Jeremy Stackawitz as President and CEO of Quotient Biodiagnostics. Jeremy has many years of commercial and strategic management experience in the life sciences industry, most recently as Director, World-wide Marketing, Immunohaematology at Ortho Clinical Diagnostics (part of Johnson & Johnson), the worlds leading supplier of blood typing and screening products.

John Allan will continue in his role as CEO of Alba Bioscience and Paul Cowan will become the Chairman of Quotient Biodiagnostics.

Paul Cowan said: “We are very pleased to have been able to appoint someone with the calibre and experience of Jeremy to lead Quotient Biodiagnostics. He is well known to the Alba Bioscience senior management team and brings a wealth of commercial knowledge and experience to the Group, particularly in the immunohaematology field.”

Jeremy Stackawitz, President and CEO of Quotient Biodiagnostics said: “Our strategy is to become the partner of choice in the immunohaematology market. The formation of Quotient Biodiagnostics will allow Quotient Bioscience to better utilise the world-class research and development infrastructure and FDAlicensed blood typing and screening products of Alba Bioscience to achieve this vision. I look forward to working with everybody at Alba on this exciting opportunity.”

Get Answers Here